{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:51:52Z","timestamp":1791474712853,"version":"4.3.4"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:sec id=\"ab-ooi260049-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Liquid biopsy is emerging as a strong biomarker for detecting and monitoring head and neck squamous cell carcinoma (HNSCC). The strongest evidence for circulating tumor DNA (ctDNA) in HNSCC comes from studies of tissue-agnostic assays detecting human papillomavirus (HPV)\u2212associated HNSCC. In HPV-negative HNSCC, the lack of broadly shared variational targets precludes the use of tissue-agnostic ctDNA approaches. An emerging alternative, tissue-informed assays, leverage patient-specific tumor variant profiles to enable individualized ctDNA detection in the blood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260049-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To measure the detection characteristics of a commercially available tissue-informed assay when compared to the standard criterion for tissue biopsies, both in the pretreatment and surveillance settings of HPV-positive and HPV-negative HNSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260049-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of adults with HNSCC who received a tissue-informed ctDNA assay as part of their oncologic treatment at a large, urban tertiary care center from December 2024 to March 2026. Data analysis was conducted from March to April 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260049-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Tumor tissue specimen, collected by fine-needle aspiration or surgical biopsy, used to create an individualized ctDNA assay for subsequent ctDNA blood tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260049-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>For the pretreatment analysis: test detection rate, miss rate, and insufficient tissue rate. In the surveillance setting: sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) on a per-test and per-patient basis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260049-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The pretreatment cohort comprised 77 patients (mean [SD] age, 65.0 [12.6] years; 28 female [36%] and 49 male [64%] individuals) and the surveillance cohort, 107 patients (mean [SD] age, 65.0 [12.1] years; 28 female [26%] and 79 male [74%] male individuals). The median (IQR) time since treatment conclusion for patients in the surveillance cohort was 18 (11-39) months. Tissue-informed ctDNA was detected in 71 of 77 patients (92.2%) in the initial pretreatment setting. In the surveillance setting, the assay demonstrated a per-test sensitivity of 95.2% (20 of 21 patients; 95% CI, 83.3%-100%), specificity of 100% (157 of 157 patients; 95% CI, 100%-100%), PPV of 100% (20 of 20 patients; 95% CI, 100%-100%), and a NPV of 99.4% (157 of 158 patients; 95% CI, 97.9%-100%). On a per-patient level, the sensitivity was 94.4% (17 of 18 patients; 95% CI, 72.7%-99.9%), specificity was 100% (89 of 89 patients; 95% CI, 95.9%-100%), PPV was 100% (17 of 17 patients; 95% CI, 80.5%-100%), and NPV was 98.9% (89 of 90 patients; 95% CI, 93.0%-99.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260049-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this cohort study, tissue-informed ctDNA assay showed excellent test creation ability in the pretreatment setting and performance metrics in the surveillance setting. Reasons for a failure rate of 7.8% in the pretreatment cohort remain unclear. These metrics support the feasibility of using this assay as a promising ctDNA approach for disease monitoring in HNSCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoto.2026.2469","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:03:50Z","timestamp":1788451430000},"page":"962","source":"Crossref","is-referenced-by-count":0,"title":["Tissue-Informed ctDNA Assay Performance in Head and Neck Squamous Cell Carcinoma"],"prefix":"10.1001","volume":"152","author":[{"given":"Ryan M.","family":"Sicard","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter V.","family":"Cooke","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Steinbaum","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Shaari","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia B.","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Kraft","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita S.","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohemmed N.","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzystoff J.","family":"Misiukiewicz","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Mount Sinai Hospital, New York, New York"},{"name":"Tisch Cancer Institute, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Pujadas","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bakst","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Mount Sinai Hospital, New York, New York"},{"name":"Tisch Cancer Institute, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Sindhu","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Mount Sinai Hospital, New York, New York"},{"name":"Tisch Cancer Institute, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Genden","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Roof","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"ooi260049r1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.clon.2010.05.016","article-title":"The value of periodic follow-up in the detection of recurrences after radical treatment in locally advanced head and neck cancer.","volume":"22","author":"Flynn","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"18","key":"ooi260049r2","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/cncr.34823","article-title":"Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols.","volume":"129","author":"Haring","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"ooi260049r3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.radonc.2007.04.001","article-title":"Tumor progression in waiting time for radiotherapy in head and neck cancer.","volume":"84","author":"Jensen","year":"2007","journal-title":"Radiother Oncol"},{"issue":"12","key":"ooi260049r4","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1001\/jamaoncol.2023.4042","article-title":"Circulating tumor HPV DNA for surveillance of HPV-positive oropharyngeal squamous cell carcinoma: a narrative review.","volume":"9","author":"Lang Kuhs","year":"2023","journal-title":"JAMA Oncol"},{"issue":"11","key":"ooi260049r5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/jamaoto.2023.1937","article-title":"Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus\u2013associated oropharyngeal cancer.","volume":"149","author":"Ferrandino","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"15","key":"ooi260049r6","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1200\/JCO.2004.05.178","article-title":"Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.","volume":"22","author":"Chan","year":"2004","journal-title":"J Clin Oncol"},{"issue":"31","key":"ooi260049r7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.7847","article-title":"Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial.","volume":"36","author":"Chan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"ooi260049r8","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41416-022-01716-7","article-title":"Liquid biopsy for minimal residual disease detection in head and neck squamous cell carcinoma (LIONESS): a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.","volume":"126","author":"Flach","year":"2022","journal-title":"Br J Cancer"},{"issue":"4","key":"ooi260049r9","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41418-024-01272-y","article-title":"Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck.","volume":"31","author":"Sanz-Garcia","year":"2024","journal-title":"Cell Death Differ"},{"issue":"15","key":"ooi260049r10","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-24-0590","article-title":"Personalized ctDNA for monitoring disease status in head and neck squamous cell carcinoma.","volume":"30","author":"Hanna","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"ooi260049r11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11912-019-0799-x","article-title":"Changes in the 8th edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications.","volume":"21","author":"Zanoni","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"13","key":"ooi260049r12","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1158\/1538-7445.AM2018-4542","article-title":"Abstract 4542: Analytical validation of the Signatera TM RUO assay, a highly sensitive patient-specific multiplex PCR NGS-based noninvasive cancer recurrence detection and therapy monitoring assay.","volume":"78","author":"Sethi","year":"2018","journal-title":"Cancer Res"},{"key":"ooi260049r13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy281.004","article-title":"Serial circulating tumor DNA analysis for detection of residual disease, assessment of adjuvant therapy efficacy and for early recurrence detection in colorectal cancer.","volume":"29","author":"Reinert","year":"2018","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"ooi260049r15","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-P4-01-02","article-title":"Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumour DNA (ctDNA) antedates overt metastatic recurrence.","volume":"79","author":"Coombes","year":"2019","journal-title":"Cancer Res"},{"key":"ooi260049r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.107002","article-title":"Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.","volume":"158","author":"Hanna","year":"2024","journal-title":"Oral Oncol"},{"issue":"20","key":"ooi260049r17","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1158\/1078-0432.CCR-23-1478","article-title":"Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance.","volume":"29","author":"Hanna","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ooi260049r18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0720-048X(99)00120-5","article-title":"Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI.","volume":"33","author":"Lell","year":"2000","journal-title":"Eur J Radiol"},{"issue":"11","key":"ooi260049r19","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/archoto.2011.181","article-title":"The benefit of early PET\/CT surveillance in HPV-associated head and neck squamous cell carcinoma.","volume":"137","author":"Zhang","year":"2011","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"3","key":"ooi260049r20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/0194599815621742","article-title":"Detecting residual\/recurrent head neck squamous cell carcinomas using PET or PET\/CT: systematic review and meta-analysis.","volume":"154","author":"Cheung","year":"2016","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"17","key":"ooi260049r21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21170","article-title":"PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2\/N3) nodal metastases in patients with squamous cell head and neck cancer.","volume":"21","author":"Mehanna","year":"2017","journal-title":"Health Technol Assess"},{"key":"ooi260049r22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.oraloncology.2019.08.011","article-title":"12 week PET-CT has low positive predictive value for nodal residual disease in human papillomavirus-positive oropharyngeal cancers.","volume":"97","author":"Rulach","year":"2019","journal-title":"Oral Oncol"},{"issue":"2","key":"ooi260049r23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2214\/AJR.22.28120","article-title":"Contemporary imaging and reporting strategies for head and neck cancer: MRI, FDG PET\/MRI, NI-RADS, and carcinoma of unknown primary\u2014AJR expert panel narrative review.","volume":"220","author":"Mukherjee","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"ooi260049r24","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hed.25425","article-title":"Posttreatment surveillance PET\/CT for HPV-associated oropharyngeal cancer.","volume":"41","author":"Corpman","year":"2019","journal-title":"Head Neck"},{"issue":"1","key":"ooi260049r25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12967-020-02330-y","article-title":"Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer.","volume":"18","author":"Rutkowski","year":"2020","journal-title":"J Transl Med"},{"key":"ooi260049r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106874","article-title":"Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.","volume":"155","author":"Roof","year":"2024","journal-title":"Oral Oncol"},{"issue":"2","key":"ooi260049r27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ohn.760","article-title":"ctDNA as an adjunct to posttreatment PET for head and neck cancer recurrence risk assessment.","volume":"171","author":"Lele","year":"2024","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ooi260049r28","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00489","article-title":"Predictive effectiveness of circulating tumor DNA in recurrent early-stage non-small cell lung cancer: an updated meta-analysis.","volume":"9","author":"Lu","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"ooi260049r29","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer.","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"ooi260049r30","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast cancer.","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"ooi260049r31","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"issue":"18","key":"ooi260049r32","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma.","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"20","key":"ooi260049r33","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer.","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ooi260049r34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.965578","article-title":"The Sinai Robotic Surgery Trial in HPV-related oropharyngeal squamous cell carcinoma (SIRS 2.0 trial): study protocol for a phase II non-randomized non-inferiority trial.","volume":"12","author":"Chai","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"ooi260049r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.02.003","article-title":"Early disease recurrence following post-operative HPV ctDNA directed active surveillance in oropharyngeal carcinoma\u2013outcomes of a prospective pilot study.","volume":"118","author":"Chen","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"ooi260049r36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ijrobp.2025.09.044","article-title":"Postoperative human papilloma virus circulating tumor DNA guided adjuvant therapy for human papilloma virus-related oropharyngeal carcinoma (PATH study).","volume":"124","author":"Chen","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"ooi260049r37","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"ooi260049r38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis.","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front Oncol"},{"key":"ooi260049r14","unstructured":"Birkenkamp-Demtr\u00f6der? K, Christensen? E, Sethi? H, . Sequencing of plasma cfDNA from patients with locally advanced bladder cancer for surveillance and therapeutic efficacy monitoring. 2018. Accessed July 30, 2026. https:\/\/www.natera.com\/wp-content\/uploads\/2020\/11\/Oncology-Clinician-Sequencing-of-Plasma-cfDNA-from-Patients-with-Locally-Advanced-Bladder-Cancer-AACR-2018.pdf"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2853313\/jamaotolaryngology_sicard_2026_oi_260049_1791389922.9436.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:00:51Z","timestamp":1791471651000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2853313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2026.2469","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}